Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeutic insights coming from a meta-analysis of the literature data.

CONCLUSION: Methotrexate at low doses, such those used for maintenance therapy of RA, predicted a decreased risk of CVE. Since methotrexate doesn't interfere with blood lipids, platelet aggregation or insulin resistance, the protective association may originate from mechanisms other than those exerted by antiplatelet drugs or statins. PMID: 25697810 [PubMed - as supplied by publisher]
Source: The Anatolian Journal of Cardiology - Category: Cardiology Authors: Tags: Anadolu Kardiyol Derg Source Type: research